查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837183

血管支架市場按產品類型、材料、輸送系統、應用和最終用戶分類－2025-2032年全球預測

Vascular Stent Market by Product Type, Material, Delivery System, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血管支架市場將成長至 171 億美元，複合年成長率為 6.09%。

關鍵市場統計數據
基準年 2024 106.5億美元
預計年份：2025年 112.6億美元
預測年份 2032 171億美元
複合年成長率 (%) 6.09%

概述血管支架的現狀，重點在於臨床促進因素、材料和輸送創新，以及對醫療保健領導者的影響。

血管支架領域已進入一個新階段，臨床需求、材料科學和輸送工程的交會融合，推動整個治療路徑的快速變化。血管成形術和置入術長期以來一直是冠狀動脈和周邊血管疾病的主要治療方法，如今，旨在提高生物相容性、降低血管再阻塞和簡化外科醫生工作流程的器械級創新正在重新定義這些技術。同時，不斷變化的患者群體和日益重視以價值為導向的醫療模式，正迫使醫療系統從長期療效、報銷影響和總成本等方面仔細評估器械的性能。

臨床醫師和醫院管理者越來越期望醫療器材不僅能滿足其急診手術需求，還能與最新的影像處理整合，減少後續併發症，並在適當情況下支援門診治療。因此，製造商需要在工程技術進步與監管要求和採購實際情況之間尋求平衡，而支付者和政策制定者則在評估新技術如何融入現有的醫療保健系統。臨床需求、技術進步和經濟評估的交匯，為在實證醫學、供應鏈韌性和相關人員參與的交匯點上，推動商業化進程的精細化策略決策奠定了基礎。

在相關人員評估下一代血管支架時，了解材料、器械結構、傳輸系統、應用性能和最終用戶環境之間的相互作用至關重要。本篇高階主管分析綜合了這些方面，旨在為產品開發、臨床應用和打入市場策略提供切實可行的見解，以應對當前和近期醫療保健領域的挑戰。

從材料突破到微創輸送技術的進步，再到監管政策的演變，關鍵的變革性轉變正在重塑血管支架的研發模式。

血管支架領域正經歷一系列變革，這些變革正在重新定義器械設計、臨床實踐和商業化路徑。材料科學的進步，包括可生物分解聚合物和精細化金屬藥物釋放型，使得器械能夠更好地適應血管生物力學，並以可控的方式分解或整合，從而解決了長期以來人們對慢性異物存在的擔憂。同時，藥物洗脫平台和表面工程技術的改進降低了血管再阻塞的風險，並將適應症擴展到更複雜的病變。

在手術操作方面，輸送系統日益複雜，其外形設計針對迂曲的解剖結構進行了最佳化，並採用了提高部署精度的機制。這些工程改進使得個人化器械選擇和定位成為可能，並可結合影像和術中引導，從而影響臨床療效和醫保報銷。值得注意的是，法律規範也在不斷發展。監管機構越來越重視上市後證據和真實世界績效指標，這會影響產品上市策略和生命週期管理。

經濟和營運方面的影響同樣重要。醫療系統越來越重視療效比較和總醫療成本，這迫使醫療設備製造商除了臨床療效外，還要證明其後續價值。此外，患者的期望和人口結構變化，特別是老化和併發症群體，也迫使臨床醫生設計出既能保證持久性能又能降低手術風險的器械。綜上所述，這些轉變要求製造商、臨床醫生和支付方更緊密地合作，協調證據產生、推廣途徑和報銷機制，以充分發揮新型血管支架創新技術的潛力。

評估美國關稅於2025年生效後對血管支架供應鏈、採購慣例、生產營運和籌資策略的累積影響

美國將於2025年實施關稅，這為血管支架相關人員的物流和採購計算引入了一個新的變數。目前，關稅已經改變了進口零件和成品的相對成本結構，迫使製造商重新評估其採購決策和供應商合約。各公司重新審視了其生產基地，積極推動供應商多元化，並加快了關於近岸外包的討論，以降低貿易政策波動帶來的風險。

醫院、心臟中心和門診手術中心的採購團隊隨即重新評估了合約策略，強調簽訂能夠確保價格穩定和供應的長期協議。這項轉變要求在控制成本和保障臨床供應連續性之間取得平衡，同時臨床團隊努力維持既定的器械選擇路徑和手術品質。同時，監管合規和品質監督仍然是重中之重，任何生產流程的轉移或變更都需要經過嚴格的驗證，以確保產品的可比性並滿足國內外監管機構的要求。

隨著時間的推移，關稅也影響了合作模式和資本配置決策。一些製造商投資建設區域製造能力，以更有效率地服務於特定的本地市場；而另一些製造商則深化與本地供應商的關係，以縮短前置作業時間並降低庫存風險。重要的是，這種累積效應不僅體現在交易層面，也體現在策略層面：企業重新評估了其應對挑戰的策略，更加重視情境規劃、雙重採購和供應鏈透明度，以應對未來的政策變化，並確保患者能夠獲得關鍵的血管藥物。

詳細的細分分析揭示了產品類型、材料配置、給藥方式、臨床用途和最終用戶設定如何決定設備策略。

細分市場層面的動態變化揭示了產品類型、材料組成、傳輸方式、臨床應用和終端用戶環境如何影響血管支架領域的研發重點和市場推廣路徑。支架可分為球囊擴張型和自動擴張型支架兩種類型，二者在工程設計重點上有顯著差異。球囊擴張型支架優先考慮精確的徑向支撐力和病變部位的錨定，而自擴張式支架則強調與外周解剖結構的貼合性和持續的向外支撐力。此外，自動擴張型支架可細分為可生物分解和不可生物分解聚合物兩種類型，分別用於實現臨時錨定和長期減少異物負荷。

輸送系統進一步區分了不同的價值提案。傳統的裸金屬支架與覆膜支架（提供屏障功能）和藥物釋放型支架（結合了機械支撐和藥物預防新生內膜增生）形成對比。冠狀動脈疾病需要最高的精準度和血管再阻塞控制，胃腸道疾病具有獨特的管腔動力學和組織相互作用，而包括上下肢在內的周邊動脈疾病則需要關注長節段的柔韌性、抗壓性和抗疲勞性。最後，最終用戶環境——門診手術中心、心臟中心或醫院——會影響器械規格和商業化策略。門診使用的器械通常需要簡化的工作流程和快速的恢復，而醫院和心臟中心的應用場景可能更注重高級功能集和與混合手術室的整合。

了解這些細分維度之間的相互關係對於設計臨床試驗、優先考慮研發投資以及製定反映不同手術環境和護理模式的細微要求的市場推廣策略至關重要。

從區域觀點探討美洲、歐洲、中東和非洲以及亞太市場的臨床應用、監管路徑和供應鏈策略

區域動態對血管支架技術的研發、監管和應用有顯著影響，既帶來了獨特的機遇，也帶來了挑戰。在美洲，先進的臨床基礎設施、高度集中的介入治療專家以及不斷完善的醫保報銷體系，共同創造了一個重視可靠臨床證據和上市後療效追蹤的市場環境。因此，該地區的醫療設備上市通常強調隨機對照試驗和真實世界證據，以推動臨床醫生採納和醫療照護機構的認可。

在歐洲、中東和非洲，監管協調工作和多樣化的醫療保健系統資金籌措模式，共同構成了複雜的市場准入挑戰。採購政策和衛生技術評估流程的差異，也要求製造商調整其價值提案和證據材料，以滿足區域和國家決策者的要求。相較之下，亞太地區對醫療程序的龐大需求，以及新型醫療服務模式的快速普及，使得在地化生產能力和監管路徑更加重要。這些監管路徑需要結合具體臨床數據，但同時也允許快速獲得有條件核准。總而言之，這些區域差異影響著製造地、臨床證據的生成以及商業性夥伴關係的策略重點，使得區域成為產品生命週期和市場推廣計畫的關鍵決定因素。

最終，採取細緻入微的區域性方法，將臨床證據策略、監管參與和供應鏈架構與當地系統的期望相協調，將提高在不同醫療保健市場成功採用和持續使用的可能性。

血管支架產業的競爭格局和策略定位，重點在於創新、夥伴關係、卓越製造和商業化策略。

領先的血管支架開發商之間的競爭動態呈現出雙重特徵：一方面注重漸進式工程改進，另一方面則致力於顛覆性平台創新。擁有深厚製造傳統的公司利用其規模優勢、成熟的臨床關係以及豐富的上市後數據來捍衛市場佔有率並爭取有利的採購條款。同時，規模較小、反應更敏捷的參與企業則專注於細分市場差異化，例如新型可生物分解聚合物配方、獨特的表面化學性質以及簡化的給藥機制，以期在臨床和商業領域站穩腳跟。這些同行之間的合作通常以許可協議、聯合開發夥伴關係和區域分銷協議的形式展開，從而在控制研發風險的同時，實現前景廣闊技術的快速推廣。

投資正日益流向那些在手術效率、長期療效和影像學相容性方面展現出顯著優勢的技術。與藥物釋放型動力學、生物可吸收基質設計和低輪廓輸送導管相關的智慧財產權組合仍然是核心競爭優勢。此外，近期趨勢表明，企業越來越重視品質系統和供應鏈可追溯性，紛紛投資於序列化、生產分析和供應商審核，以滿足監管要求和客戶需求。策略併購和選擇性聯盟也正在重塑競爭格局，使企業能夠拓展臨床應用範圍、增強技術能力並加速產品進入新地域市場的速度。

對於市場參與企業，規模、創新、監管合規和合作策略之間的相互作用，不僅決定了他們的短期競爭地位，也決定了他們在既重視臨床卓越性又重視營運韌性的市場中的長期永續性。

為產業領導者提供可操作的建議，以加強研發合作、供應鏈韌性、監管參與和商業化效率。

行業領導者可以採取切實措施，將他們的洞察轉化為永續的競爭優勢，並改善患者療效。首先，將研發重點與具有臨床意義的終點指標和醫療系統價值指標結合，可以加強醫保報銷談判，並促進臨床醫師採納相關技術。投資上市後證據產生和真實世界資料收集，可以檢驗療效聲明，並促進其融入臨床診療路徑。其次，應將供應鏈韌性提升為策略重點。雙重採購、庫存最佳化和區域生產方案可以實現對臨床需求的快速反應，同時減輕政策變化和物流中斷的影響。

第三，制定針對終端使用者環境（例如門診手術中心、心臟中心和醫院）的清晰商業化路徑，可以使設備屬性與手術要求和工作流程實際情況相匹配，從而提高產品普及率。第四，儘早積極地與監管機構就研究設計和上市後監測進行溝通，可以降低核准風險並加速產品進入市場。第五，考慮將技術差異化與銷售能力結合的夥伴關係模式。共同開發和許可可以加快產品上市速度，並共用資源以產生實證醫學證據。最後，由於實際操作經驗是決定患者長期偏好的關鍵因素，因此應投資於強調手術效率和結果追蹤的臨床醫生培訓和推廣計畫。

這些措施共同構成了一個連貫的策略，平衡了技術領先性、商業性實用性和營運穩健性，使我們在快速發展的血管支架領域取得成功。

一套綜合的調查方法，結合了專家訪談、二手證據整理、細分分析和情境規劃，旨在提供可靠且可操作的洞見。

本分析的調查方法結合了專家定性訪談、系統性的二手研究和資料三角驗證，以得出可靠且可驗證的結論。主要資料來源包括對介入性心臟病專家、血管外科醫師、採購負責人和法規事務專家的結構化訪談，並輔以器械工程師和生產營運主管的訪談。這些觀點有助於我們從背景層面理解醫療機構的臨床實務模式、器材性能優先順序和採購考量。

本研究採用二手資料梳理法律規範、器材核准途徑和已發表的臨床證據，同時嚴格控制對檢驗資訊來源的依賴。在條件允許的情況下，整合定量資料以支持主題結論，並著重於多源資料交叉驗證，以檢驗觀察結果。分析方法包括交叉細分分析，以了解產品類型、材料、給藥系統、應用和最終用戶之間的相互作用；以及情境分析，以探討關稅等政策變化的影響。品質保證程序包括來源核實、同行評審和對研究結果的反覆完善，以確保研究結果清晰、相關且對決策者俱有可操作性。

倫理考量、專家貢獻的保密性以及對應用調查方法的堅持，確保了結論以證據為基礎，並對行業相關人員有戰略意義。

總結部分重點闡述了技術創新、監管壓力和供應鏈策略的交匯點，這些因素將塑造血管支架的未來。

總之，血管支架領域正處於曲折點，材料創新、改進的輸送系統、監管預期和政策轉變交織在一起，既帶來了挑戰，也帶來了機會。包括可生物分解聚合物、增強型藥物傳輸技術和更薄的輸送系統在內的技術進步，正在拓展治療冠狀動脈、胃腸道和周邊動脈疾病的臨床套件，同時也對循證醫學證據的生成和生命週期管理提出了新的考慮。政策發展和貿易行動凸顯了供應鏈策略的重要性，鼓勵各組織在不犧牲臨床或品質標準的前提下，追求韌性和區域合作。

從策略角度來看，製造商和醫療服務提供者必須平衡臨床療效、經濟價值和營運可靠性這三者的重要性。成功的關鍵在於採用整合式方法，將嚴謹的臨床證據與適應性強的生產和採購模式、針對不同終端使用者環境的商業化策略以及積極的監管溝通結合。透過將投資集中於臨床獲益和系統價值融合的領域，產業參與者可以加速產品推廣應用，改善患者預後，並建立永續的商業模式。本分析探討的主題為高階主管提供了藍圖，幫助他們在不斷發展的血管支架領域中確定工作重點、管理風險並掌握機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 具有最佳化藥物傳遞特性的生物可吸收血管支架的應用日益廣泛
  • 無聚合物藥物釋放型支架的進展可降低冠狀動脈介入治療的發炎風險
  • 透過整合血管內成像和人工智慧技術，實現個體化的支架置入計劃
  • 開發3D列印的患者特異性支架植入，以改善解剖結構匹配度及治療效果。
  • 一種新型奈米塗層技術可促進支架內皮癒合並降低血管再阻塞率。
  • 遠端橈動脈入路技術的進步影響了支架的設計，提高了手術安全性和舒適度。
  • 新型鎂基生物可吸收支架在全球多個市場獲得監管部門核准的數量增加
  • 新興國家由於患者數量不斷增加而面臨的成本壓力將推動專利到期藥物釋放型支架的普及。
  • 周邊動脈疾病治療需求的成長推動了髂動脈和股動脈支架設計的創新。
  • 將遠端監測和數位療法整合到支架置入術後的患者管理流程中。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 血管支架市場（依產品類型分類）

  • 球囊擴張型支架
  • 自動擴張型支架

9. 按材料分類的血管支架市場

  • 金屬支架
  • 聚合物支架
    • 可生物分解聚合物
    • 不可生物分解聚合物

10. 依輸送系統分類的血管支架市場

  • 裸金屬支架
  • 覆膜支架
  • 藥物釋放型支架

第11章 血管支架市場依應用領域分類

  • 冠狀動脈疾病
  • 消化系統疾病
  • 周邊動脈疾病
    • 下肢
    • 上肢

第12章 血管支架市場（依最終用戶分類）

  • 門診手術中心
  • 心臟中心
  • 醫院

第13章 各地區血管支架市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血管支架市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血管支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Amaranth Medical, Inc.
    • Artivion Inc.
    • B. Braun SE
    • Becton, Dickinson and Company
    • Biotronik SE & Co. KG
    • Blue Sail Medical Co., Ltd
    • Boston Scientific Corporation
    • Cardinal Health, Inc.
    • Cook Group Incorporated
    • Elixir Medical Corporation
    • Endologix LLC
    • iVascular, SLU
    • Kaneka Corporation
    • Kyoto Medical Planning Co., Ltd.
    • Lepu Medical Technology（Beijing）Co.,Ltd.
    • Lombard Medical Ltd.
    • Medtronic PLC
    • Meril Life Sciences Pvt. Ltd
    • Microport Scientific Corporation
    • Otsuka Medical Devices Co., Ltd.
    • Purple MicroPort Cardiovascular Pvt. Ltd
    • Sahajanand Medical Technologies Limited
    • Stryker Corporation
    • Terumo Corporation
    • Translumina GmbH
    • WL Gore & Associates, Inc.
Product Code: MRR-034B5003037F

The Vascular Stent Market is projected to grow by USD 17.10 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.65 billion
Estimated Year [2025] USD 11.26 billion
Forecast Year [2032] USD 17.10 billion
CAGR (%) 6.09%

Executive overview of the vascular stent landscape emphasizing clinical drivers, material and delivery innovations, and implications for healthcare leaders

The vascular stent landscape has entered a phase where clinical necessity, material science, and delivery engineering intersect to drive rapid change across care pathways. Angioplasty and stenting procedures, long established as core interventions for coronary and peripheral vascular disease, are being redefined by device-level innovation that targets improved biocompatibility, reduced restenosis, and simpler operator workflows. At the same time, evolving patient demographics and growing emphasis on value-based care are prompting health systems to scrutinize device performance across long-term outcomes, reimbursement impact, and total cost of care.

Clinicians and hospital administrators increasingly expect devices that not only meet acute procedural needs but also integrate with modern imaging, reduce downstream complications, and enable ambulatory delivery where appropriate. Consequently, manufacturers are balancing engineering advances with regulatory requirements and procurement realities, while payers and policy-makers assess how new technologies fit into existing coverage frameworks. This confluence of clinical demand, technological progress, and economic evaluation sets the stage for nuanced strategic decision-making, where commercialization plays out at the intersection of evidence generation, supply chain resilience, and stakeholder engagement.

As stakeholders evaluate the next generation of vascular stents, understanding the interplay between materials, device architecture, delivery systems, application-specific performance, and end-user settings becomes essential. This executive analysis synthesizes those dimensions to highlight actionable insights for product development, clinical adoption, and market access strategies that are responsive to current and near-term healthcare imperatives.

Major transformative shifts reshaping vascular stent development from materials breakthroughs to minimally invasive delivery advances and regulatory evolution

The vascular stent environment is experiencing a series of transformative shifts that together are redefining device design, clinical practice, and commercialization pathways. Advances in material science, including the maturation of biodegradable polymers and refined metallic alloys, are enabling devices that better match vascular biomechanics and degrade or integrate in a controlled manner, thereby addressing long-standing concerns about chronic foreign body presence. Concurrently, enhancements in drug-eluting platforms and surface engineering are reducing restenosis risk and expanding indications into more complex lesions.

On the procedural front, delivery systems are becoming more sophisticated, with profiles optimized for tortuous anatomy and mechanisms that improve deployment precision. These engineering changes are accompanied by imaging and intraprocedural diagnostics that allow personalized device selection and positioning, which in turn influence clinical outcomes and reimbursement narratives. Importantly, regulatory frameworks are also evolving; authorities are placing greater emphasis on post-market evidence and real-world performance metrics, which affects product launch strategies and lifecycle management.

Economic and operational forces are equally consequential. Health systems are emphasizing comparative effectiveness and total cost of care, prompting device manufacturers to demonstrate not only clinical efficacy but also downstream value. Finally, patient expectations and demographics-particularly aging populations with comorbidities-are pushing clinicians toward devices that balance durable performance with reduced procedural risk. Taken together, these shifts require manufacturers, clinicians, and payers to collaborate more intensively on evidence generation, adoption pathways, and reimbursement alignment to realize the full potential of new vascular stent innovations.

Assessment of the cumulative effects of United States tariffs enacted in 2025 on vascular stent supply chains, procurement practices, manufacturing operations, and sourcing strategies

The introduction of United States tariffs in 2025 introduced a new variable into the logistics and procurement calculus for vascular stent stakeholders. In the immediate term, tariffs altered the relative cost structure of imported components and finished devices, compelling manufacturers to reassess sourcing decisions and supplier agreements. Beyond the arithmetic of import duties, the policy change catalyzed broader strategic responses: firms re-examined production footprints, engaged in supplier diversification, and accelerated discussions about nearshoring to mitigate exposure to trade policy volatility.

Procurement teams within hospitals, cardiac centers, and ambulatory surgical settings responded by revising contracting strategies, emphasizing longer-term agreements that offered price certainty and supply assurances. These shifts required negotiation of terms that balanced cost containment with continuity of clinical supply, while clinical teams worked to preserve device preference pathways and procedural quality. Meanwhile, regulatory compliance and quality oversight remained central; relocating or altering manufacturing processes demanded rigorous validation to ensure product equivalence and to satisfy both domestic and international regulators.

Over time, the tariffs also influenced partnership models and capital allocation decisions. Some manufacturers invested in regional manufacturing capabilities to serve specific geographic markets more efficiently, while others deepened relationships with local suppliers to shorten lead times and reduce inventory risk. Importantly, the cumulative effect was not only transactional but strategic: organizations recalibrated their approach to resilience, placing greater emphasis on scenario planning, dual sourcing, and supply chain transparency to withstand future policy shifts and sustain patient access to critical vascular therapies.

In-depth segmentation analysis revealing how product type, material composition, delivery modality, clinical application, and end-user settings determine device strategy

Segment-level dynamics reveal how product type, material composition, delivery modality, clinical application, and end-user setting collectively shape development priorities and adoption pathways in the vascular stent domain. Devices classified by product type as balloon-expandable stents and self-expanding stents continue to diverge in engineering emphasis; balloon-expandable platforms prioritize precise radial force and lesion scaffolding, whereas self-expanding designs focus on conformability and chronic outward force for peripheral anatomy. Material choices reinforce these functional trade-offs: metallic stents, leveraging advanced alloys, deliver proven radial strength and radiopacity, while polymeric stents-split into biodegradable polymers and non-biodegradable polymers-open pathways for transient scaffolding and reduced long-term foreign body burden.

Delivery systems further differentiate value propositions. Traditional bare metal stents are contrasted with covered stents that provide barrier functions, and drug-eluting stents that combine mechanical support with pharmacologic prevention of neointimal hyperplasia. Application-specific requirements also drive segmentation: coronary artery disease demands utmost precision and restenosis control, gastrointestinal disease introduces unique luminal dynamics and tissue interactions, and peripheral artery disease-encompassing lower extremities and upper extremities-requires attention to long segment flexibility, compression resistance, and fatigue durability. Finally, end-user settings such as ambulatory surgical centers, cardiac centers, and hospitals influence device specifications and commercialization tactics; devices adopted in ambulatory contexts often need streamlined workflows and rapid recovery profiles, whereas hospital and cardiac center use cases may prioritize advanced feature sets and integration with hybrid operating suites.

Understanding how these segmentation dimensions interrelate is essential for designing clinical trials, prioritizing R&D investment, and tailoring market access approaches that reflect the nuanced requirements of distinct procedural contexts and care delivery models.

Regional perspectives on clinical adoption, regulatory pathways, and supply chain strategy across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics exert a powerful influence on how vascular stent technologies are developed, regulated, and adopted, producing geography-specific opportunities and constraints. In the Americas, a combination of advanced clinical infrastructure, concentrated centers of interventional expertise, and evolving reimbursement frameworks creates a market environment that rewards robust clinical evidence and post-market outcome tracking. Consequently, device launches in this region typically emphasize randomized and real-world evidence to accelerate clinician adoption and payer acceptance.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse health system financing models create a complex mosaic for market entry. Variations in procurement policy and health technology assessment processes mean that manufacturers must adapt value propositions and evidence packages to satisfy regional and national decision-makers. In contrast, the Asia-Pacific region presents a mix of high-volume procedural demand and rapid adoption of new delivery models, with an increasing emphasis on localized manufacturing capabilities and regulatory pathways that can expedite conditional approvals while requiring contextually relevant clinical data. Taken together, these regional distinctions shape strategic priorities for manufacturing location, clinical evidence generation, and commercial partnerships, making geography a key determinant of product lifecycles and go-to-market planning.

Ultimately, a nuanced regional approach that aligns clinical evidence strategies, regulatory engagement, and supply chain architecture with local system expectations enhances the likelihood of successful adoption and sustained utilization across diverse health markets.

Competitive dynamics and strategic positioning across the vascular stent industry highlighting innovation, partnerships, manufacturing excellence, and commercialization tactics

Competitive dynamics among leading vascular stent developers are characterized by a dual emphasis on incremental engineering refinement and disruptive platform innovation. Companies with deep manufacturing heritage leverage scale, established clinical relationships, and extensive post-market datasets to defend share and negotiate favorable procurement terms. Simultaneously, smaller and more agile entrants focus on niche differentiation-such as novel biodegradable polymer formulations, unique surface chemistries, or simplified delivery mechanisms-to create clinical and commercial footholds. Collaboration between these cohorts often takes the form of licensing agreements, co-development partnerships, and localized distribution deals that enable rapid scaling of promising technologies while managing development risk.

Investment flows are increasingly directed toward technologies that demonstrate clear procedural efficiency gains, improved long-term outcomes, or strong compatibility with imaging modalities. Intellectual property portfolios around drug elution kinetics, bioresorbable matrix design, and low-profile delivery catheters remain central competitive assets. Moreover, recent trends show heightened attention to quality systems and supply chain traceability, with companies investing in serialization, manufacturing analytics, and supplier auditing to meet regulatory expectations and customer demands. Strategic M&A activity and selective partnerships are also shaping the competitive landscape, allowing firms to expand clinical reach, augment technological capabilities, or enter new geographic markets with reduced time-to-adoption.

For industry participants, the interplay of scale, innovation focus, regulatory compliance, and partnership strategy determines not only short-term competitive positioning but also long-term sustainability in a market that prizes both clinical excellence and operational resilience.

Actionable recommendations for industry leaders to strengthen R&D alignment, supply chain resilience, regulatory engagement, and commercialization effectiveness

Industry leaders can take concrete steps to translate insight into durable competitive advantage and improved patient outcomes. First, aligning R&D priorities with clinically meaningful endpoints and health system value metrics will strengthen reimbursement discussions and clinician adoption. Investing in post-market evidence generation and real-world data collection will validate performance claims and facilitate inclusion in care pathways. Second, supply chain resilience should be elevated to a strategic priority: dual sourcing, inventory optimization, and regional manufacturing options can reduce exposure to policy shifts and logistic disruptions while enabling faster response to clinical demand.

Third, developing clear commercialization pathways tailored to end-user settings-such as ambulatory surgical centers, cardiac centers, and hospitals-will improve uptake by matching device attributes to procedural requirements and workflow realities. Fourth, engaging with regulators early and proactively on study design and post-market surveillance reduces approval risk and accelerates market entry. Fifth, consider partnership models that combine technological differentiation with distribution strength; co-development and licensing can speed time-to-market and allow resource sharing for evidence generation. Finally, invest in clinician training and adoption programs that emphasize procedural efficiency and outcomes tracking, as hands-on familiarity remains a key determinant of long-term device preference.

Taken together, these actions create a cohesive strategy that balances technological leadership with commercial pragmatism and operational robustness, positioning organizations to succeed in a rapidly evolving vascular stent environment.

Comprehensive research methodology combining expert interviews, secondary evidence curation, segmentation analysis, and scenario planning to ensure robust actionable insights

The research approach underpinning this analysis integrates qualitative expert engagement with systematic secondary research and data triangulation to produce robust, defensible insights. Primary inputs included structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and regulatory affairs specialists, complemented by device engineers and manufacturing operations executives. These perspectives provided contextual understanding of clinical practice patterns, device performance priorities, and procurement considerations across care settings.

Secondary research was used to map regulatory frameworks, device approval pathways, and published clinical evidence, with careful curation to avoid reliance on unverified sources. Quantitative inputs were synthesized where available to support thematic conclusions, but the emphasis remained on triangulating multiple data sources to validate observations. Analytical methods included cross-segmentation analysis to understand how product type, material, delivery system, application, and end-user interact, and scenario analysis to explore the implications of policy shifts such as tariffs. Quality assurance procedures included source verification, expert review, and iterative refinement of findings to ensure clarity, relevance, and practical applicability for decision-makers.

Ethical considerations, confidentiality of expert contributions, and adherence to applicable research standards guided the methodology throughout, ensuring that conclusions are evidence-based and oriented toward strategic utility for industry stakeholders.

Concluding synthesis emphasizing the intersection of technological innovation, regulatory pressure, and supply chain strategy shaping the vascular stent future

In conclusion, the vascular stent sector stands at an inflection point where material innovation, delivery system refinement, regulatory expectations, and policy shifts intersect to create both challenges and opportunities. Technological advances such as biodegradable polymers, enhanced drug-elution technologies, and low-profile delivery systems are expanding the clinical toolkit for treating coronary, gastrointestinal, and peripheral arterial disease, while simultaneously raising new considerations for evidence generation and lifecycle management. Policy developments and trade measures have amplified the importance of supply chain strategy, prompting organizations to pursue resilience and regional alignment without sacrificing clinical or quality standards.

Strategically, manufacturers and healthcare providers must balance the imperatives of clinical performance, economic value, and operational reliability. Success will hinge on integrated approaches that combine rigorous clinical evidence with adaptive manufacturing and procurement models, targeted commercialization strategies for varied end-user environments, and proactive regulatory engagement. By focusing investments where clinical benefit and system value converge, industry participants can accelerate adoption, improve patient outcomes, and create sustainable commercial models. The themes explored in this analysis provide a roadmap for executives to prioritize initiatives, manage risk, and capture opportunities in the evolving vascular stent landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of bioresorbable vascular scaffolds with optimized drug delivery profiles
  • 5.2. Advances in polymer-free drug-eluting stents reducing inflammation risks in coronary interventions
  • 5.3. Integration of intravascular imaging and artificial intelligence for personalized stent placement planning
  • 5.4. Development of 3D printed patient-specific stent implants to improve anatomical conformity and outcomes
  • 5.5. Emerging nanocoating technologies enhancing endothelial healing and reducing restenosis rates in stents
  • 5.6. Rise of distal radial access techniques influencing stent design for improved procedural safety and comfort
  • 5.7. Increasing regulatory approvals of novel magnesium-based bioresorbable stents across multiple global markets
  • 5.8. Cost pressures driving adoption of off-patent drug-eluting stents in emerging economies with growing patient pools
  • 5.9. Expansion of peripheral artery disease treatment demand fueling innovation in iliac and femoral stent designs
  • 5.10. Integration of remote monitoring and digital therapeutics for post-stent implantation patient management pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Stent Market, by Product Type

  • 8.1. Balloon-Expandable Stents
  • 8.2. Self-Expanding Stents

9. Vascular Stent Market, by Material

  • 9.1. Metallic Stents
  • 9.2. Polymeric Stents
    • 9.2.1. Biodegradable Polymers
    • 9.2.2. Non-Biodegradable Polymers

10. Vascular Stent Market, by Delivery System

  • 10.1. Bare Metal Stents
  • 10.2. Covered Stents
  • 10.3. Drug Eluting Stents

11. Vascular Stent Market, by Application

  • 11.1. Coronary Artery Disease
  • 11.2. Gastrointestinal Disease
  • 11.3. Peripheral Artery Disease
    • 11.3.1. Lower Extremities
    • 11.3.2. Upper Extremities

12. Vascular Stent Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Centers
  • 12.3. Hospitals

13. Vascular Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vascular Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vascular Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Amaranth Medical, Inc.
    • 16.3.3. Artivion Inc.
    • 16.3.4. B. Braun SE
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Biotronik SE & Co. KG
    • 16.3.7. Blue Sail Medical Co., Ltd
    • 16.3.8. Boston Scientific Corporation
    • 16.3.9. Cardinal Health, Inc.
    • 16.3.10. Cook Group Incorporated
    • 16.3.11. Elixir Medical Corporation
    • 16.3.12. Endologix LLC
    • 16.3.13. iVascular, S.L.U
    • 16.3.14. Kaneka Corporation
    • 16.3.15. Kyoto Medical Planning Co., Ltd.
    • 16.3.16. Lepu Medical Technology(Beijing)Co.,Ltd.
    • 16.3.17. Lombard Medical Ltd.
    • 16.3.18. Medtronic PLC
    • 16.3.19. Meril Life Sciences Pvt. Ltd
    • 16.3.20. Microport Scientific Corporation
    • 16.3.21. Otsuka Medical Devices Co., Ltd.
    • 16.3.22. Purple MicroPort Cardiovascular Pvt. Ltd
    • 16.3.23. Sahajanand Medical Technologies Limited
    • 16.3.24. Stryker Corporation
    • 16.3.25. Terumo Corporation
    • 16.3.26. Translumina GmbH
    • 16.3.27. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VASCULAR STENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VASCULAR STENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VASCULAR STENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VASCULAR STENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VASCULAR STENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR STENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GCC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GCC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. GCC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 274. GCC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 276. GCC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 277. GCC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 278. GCC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 279. GCC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. GCC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. GCC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. GCC VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. G7 VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. G7 VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. G7 VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 322. G7 VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 323. G7 VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 324. G7 VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 325. G7 VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 326. G7 VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 327. G7 VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. G7 VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. G7 VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 330. G7 VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 331. G7 VASCULAR STENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. G7 VASCULAR STENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 334. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 335. NATO VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. NATO VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. NATO VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 338. NATO VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 339. NATO VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2024 (USD MILLION)
  • TABLE 340. NATO VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2025-2032 (USD MILLION)
  • TABLE 341. NATO VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 342. NATO VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 343. NATO VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. NATO VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. NATO VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 346. NATO VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 347. NATO VASCULAR STENT MARKET SIZE, BY END USER